反应详情

In a similar manner to that described in example 196, from ethyl 7-[(4-fluorophenyl)methyl]-4-hydroxy-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxylate(10 mg, 0.028 mmol) described in example 92 and 5-(aminomethyl)-2(1H)-pyridinone (50 mg, 0.403 mmol), was prepared 7-[(4-fluorophenyl)methyl]-4-hydroxy-1-methyl-2-oxo-N-[(6-oxo-1,6-dihydro-3-pyridinyl)methyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide (7 mg, 58% yield) as a white solid after purification by reverse phase HPLC. 1H NMR (CDCl3) δ 10.51 (br s, 1 H), 8.59 (s, 1 H), 7.49 (d, J=9.6 Hz, 1 H), 7.39 (s, 2 H), 7.17-7.13 (m, 2 H), 7.04-6.94 (m, 2 H), 6.56 (d, J=9.6 Hz, 1 H), 4.38 (d, J=6 Hz, 2 H), 4.13 (s, 2 H), 3.56 (s, 3 H); HRMS m/z calcd for C23H20N4O4F: 435.1469 Found: 435.1470.